The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis
| Autor: | Eilidh McCulloch, Mary Waterston, S Sbrana, Peter David Eckersall, Alessandra Rota, Veronica Marchetti, David L.H. Bennett |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Male
medicine.medical_specialty Pathology Lameness Animal Stifle joint Osteoarthritis Gastroenterology C-reactive protein Cruciate ligament chemistry.chemical_compound Dogs Internal medicine Cytology medicine Synovial fluid Animals Cyclooxygenase Inhibitors Cruciate disease Dog Diseases Phenylacetates General Veterinary biology Robenacoxib business.industry Diphenylamine General Medicine medicine.disease Stifle veterinary(all) Radiography medicine.anatomical_structure chemistry Lameness biology.protein Female business Research Article |
| Zdroj: | BMC Veterinary Research |
| ISSN: | 1746-6148 |
| DOI: | 10.1186/1746-6148-9-42 |
| Popis: | Background: Robenacoxib is a novel and highly selective inhibitor of COX-2 in dogs and cats and because of its acidic nature is regarded as being tissue-selective. Thirty four dogs with stifle osteoarthritis secondary to failure of the cranial cruciate ligament were recruited into this study. Lameness, radiographic features, synovial cytology and C-reactive protein concentrations in serum and synovial fluid were assessed before and 28 days after commencing a course of Robenacoxib at a dose of 1 mg/kg SID.\ud \ud Results: There was a significant reduction in the lameness score (P \ud \ud Conclusions: Robenacoxib proved effective in reducing lameness in dogs with failure of the cranial cruciate ligament and osteoarthritis of the stifle joint. The drug also reduced levels of C-reactive protein in the synovial fluid taken from the affected stifle joint. Robenacoxib appears to reduce articular inflammation as assessed by C-reactive protein which supports the concept that Robenacoxib is a tissue-selective non-steroidal anti-inflammatory drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|